Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Serina Therapeutics ( (SER) ) has issued an announcement.
On August 18, 2025, Serina Therapeutics‘ Board of Directors amended the company’s bylaws to introduce safe harbor procedures for transactions involving directors, officers, and controlling stockholders with potential conflicts of interest. Additionally, the amendment expanded the forum selection clause to cover stockholder claims related to the corporation’s business, conduct, or rights, potentially impacting how legal disputes are managed and enhancing corporate governance transparency.
The most recent analyst rating on (SER) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.
Spark’s Take on SER Stock
According to Spark, TipRanks’ AI Analyst, SER is a Neutral.
Serina Therapeutics faces significant financial challenges, which heavily impact its overall stock score. The technical analysis provides mixed signals, and the valuation is unattractive due to negative profitability. However, the recent corporate event regarding SER-270 offers a positive outlook for future growth potential. The overall score reflects these mixed factors, with financial performance being the most significant detractor.
To see Spark’s full report on SER stock, click here.
More about Serina Therapeutics
Serina Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing innovative therapeutics. The company is known for its proprietary polymer technology aimed at improving drug delivery and efficacy.
Average Trading Volume: 21,627
Technical Sentiment Signal: Sell
Current Market Cap: $51.36M
Find detailed analytics on SER stock on TipRanks’ Stock Analysis page.